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The norovirus NS6 protease is a key target for anti-viral drug
development. Noroviruses encode a 2200 amino acid polyprotein
which is cleaved by this critical protease at five defined boundary
substrates into six mature non-structural (NS) proteins. Studies
of the human norovirus (HNV) NS6 protease, in the context of
a full ORF1 polyprotein, have been severely hampered because
HNVs are not culturable. Thus, investigations into the HNV NS6
protease have been largely restricted to in vitro assays using
Escherichia coli-expressed, purified enzyme. The NS6 protease
is formed of two distinct domains joined by a linking loop.
Structural data suggest that domain 2 of the protease possesses
substantial substrate binding pockets which form the bulk of the
interactions with the NS boundaries and largely dictate boundary
specificity and cleavage. We have constructed chimaeric murine
norovirus (MNV) genomes carrying individual domains from
the HNV protease and demonstrated by cell transfection that
chimaeric HNV proteases have functional activity in the context
of the full-length ORF1 polyprotein. Although domain 2 primarily
confers boundary specificity, our data suggest that an inter-domain
interaction exists within HNV NS6 protease which influences
cleavage of specific substrates. The present study also shows that
chimaeric MNVs provide improved models for studying HNV
protein function in the context of a full ORF1 polyprotein.
Key words: murine norovirus (MNV), norovirus, protease,
polyprotein, positive sense, proteolysis.
INTRODUCTION
Noroviruses are members of the calicivirus family of positive-
sense, single-stranded RNA viruses. Human noroviruses (HNVs)
are the leading cause of acute non-bacterial gastroenteritis,
with epidemics common in semi-enclosed communities such as
hospitals, schools and cruise ships. Currently, there is no vaccine
or anti-viral therapy for treating HNV infection.
A major factor limiting the progress of vaccine and anti-viral
development is the lack of a robust cell culture system for studying
the molecular mechanisms of HNV infection and pathogenesis,
with most recent studies using murine norovirus (MNV) which
can be cultured, as a surrogate for studying HNV biology.
The norovirus genome is translated into three open reading
frames (ORFs), ORF1, ORF2 and ORF3 [1–3]. ORF2 and
ORF3 encode the major and minor viral structural proteins, VP1
and VP2, respectively [4,5]. ORF1 encodes a large polyprotein
precursor of approximately 200 kDa which is cleaved into the six
mature non-structural (NS) proteins, NS1/2-NS7, by the ORF1-
encoded NS6 protease [6–15]. It is likely that all the viral NS
proteins are essential for viral RNA replication, as is complete
processing of the ORF1 polyprotein, making the NS6 protease
an attractive target for anti-viral therapy [7,11,16,17]. Efforts to
study the HNV protease in cellulo have been severely hampered
due to the limited systems available for studying HNVs. NS6-
mediated scissile bond cleavage of the ORF1 polyprotein occurs
at five NS boundaries, defined by Q-G, E-G or E-A at the cleavage
junctions, with the addition of Q-N in the case of the MNV
[6,16–21]. Cleavage of the five NS boundaries follows a preferred
temporal order, which is likely to be partially dictated by the amino
acids in the P5–P2 and P2′ positions flanking the scissile bond
dipeptide (P1–P1′) [6,7,16,22–25]. Comparison of the amino acid
sequences flanking the scissile bonds between HNV and MNV
reveal some significant diversity, suggesting differences in the
temporal processing of the HNV and MNV ORF1 polyproteins.
Previous studies have reported the crystal structures of HNV
and MNV proteases, either alone or in complex with natural
substrate peptides and peptide-like inhibitors [13,26–29]. The
norovirus NS6 protease is a cysteine protease that adopts a
chymotrypsin-like fold consisting of two well-defined domains,
a β-sheet domain 1 and a β-barrel domain 2, joined by the 20-
residue lpeI loop. The two domains are separated by the active site
groove, consisting of a catalytic triad of cysteine (Cys139), histidine
(His30) and either a glutamic acid (Glu54) or aspartic acid (Asp54)
residue in HNV and MNV respectively [13,23,27,28,30–32].
Specific subsites or ‘pockets’ within the protease, which interact
with the substrate boundary upstream of the cleavage junction,
are well defined and named S5–S1 according to the standard
nomenclature for proteases [33]. Crystal structures of the protease
in complex with boundary substrates show that, outside the
catalytic triad, the majority of the substrate binding interactions
are within domain 2 of the protease, in particular within the S2
and S4 pockets, which interact with the P2 and P4 boundary
residues, respectively [26,28,29]. Upon substrate binding, the
HNV protease can undergo a conformational change in the
S2 and S4 pockets to accommodate variations in the P2–P5
boundary residues, and it has been suggested that this mechanism
is how the HNV protease recognizes cleavage boundaries with
different affinities [29]. In comparison with the S5–S1 pockets,
the prime-side binding pockets, which interact with the P′ residues
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downstream of the cleavage junction, are less well defined.
Analysis of the residues which occupy the boundary P1′ position
suggest residues with smaller side-chain groups are preferred,
therefore it is likely only a small S1′ pocket is required, and
biochemical studies suggest the P2′ residue has only minor
effects on cleavage efficiency [25]. However, there is a relative
paucity of structural information on the prime-side interactions
and inspection of the available crystal structures reveals that the
enzyme does not appear to have a major binding groove extending
beyond the S1′ pocket.
Since domain 2 of the protease contains the majority of the
residues which form the S5–S1 pockets and interact with the
cleavage boundary, we hypothesized that domain 2 dominates
boundary specificity to dictate cleavage of the ORF1 polyprotein.
To investigate this hypothesis, we made chimaeric MNV
constructs by exchanging individual domains from the MNV NS6
protease, or the protease in its entirety, with the equivalent
portion from the HNV protease. In doing so, we demonstrate
that chimaeric MNV/HNV proteases show functional activity
and that the HNV protease is able to process the MNV ORF1
polyprotein. In addition, results presented in the present study
suggest that although domain 2 may confer the majority of the
boundary specificity, an inter-domain interaction within HNV
NS6 influences cleavage at specific NS boundaries. Furthermore,
we propose that these ‘humanized’ MNV constructs, which carry
a HNV NS6 protease in place of the MNV protease, provide
an additional model for further understanding of HNV protease
function in cellulo, within the context of a full ORF1 polyprotein.
MATERIALS AND METHODS
Plasmid construction
The polII based MNV plasmid expression construct, pMNV*,
from which all pMNV* mutants were derived, has been described
previously [34]. The sequence of all the primers used in the present
study can be found in Supplementary Table S1. Introduction of
the GDD>GAD polymerase inactivating mutation was performed
by PCR using primers GAD_Fwd and GAD_Rvs and the
subsequent AfeI–XhoI fragment was cloned into AfeI–XhoI-
digested pMNV*.
To introduce the entire Southampton virus (SV) NS6 sequence
mutagenic PCR was used, with first round amplification
using primers SV3C_Fwd + SVD2_MNV3CDP6-P2′_Rvs
with template pT7-SV3BCD (shown in Figure S1 and
described below) [35], to amplify the entire SV NS6
fragment with flanking MNV* sequence. First round PCRs
to amplify the upstream and downstream MNV* sequence
were performed using primers MNV_4F + SV3C_Rvs
and primers SVD2_MNV3CDP6P2′_Fwd + MNV_6R, with
template pMNV*. The main PCR product from the second round
of amplification, generated from products of the first round in
combination with primers MNV_4F and MNV_6R, was digested
with AflII and cloned into AflII-digested pMNV* to make
pMNV*-SV3C.
Generation of the domain swap mutants was performed by
standard overlapping 2-step PCR mutagenesis [36]. Primers
MNV_SV3CD1_Fwd + MNV_6R and MNV_SV3CD1_Rvs +
MNV_4F were used in the first round amplification with templates
pMNV* and pMNV*-SV3C, respectively. The first round PCR
products were used in the second round of amplification with
primers MNV_4F and MNV_6R and the AflII-digested second
round PCR product cloned into AflII-digested pMNV*. The
domain 2 swap was generated using a similar cloning strategy
involving primers MNV_SV3CD2_Fwd + MNV_6R and MNV
SV3CD2_Rvs + MNV_4F in the first round reactions with
templates pMNV*-SV3C and pMNV*, respectively.
The AK29TT and D54E coding changes were introduced using
standard two-step PCR mutagenesis, with first round reactions
using primers MNV3CD1_AK29TT_Fwd or MNV3CD1_D54E_
Fwd with MNV_6R and MNV3CD1_AK29TT_Rvs or
MNV3CD1_D54E_Rvs with MNV_4F, with template pMNV*-
SV3CD1. The second round PCR products, generated using
the products from the first round and primers MNV_4F +
MNV_6R, were digested with AflII and cloned into AflII-
digested pMNV*. The same strategy was used to introduce
the TT29AK and E54D mutations into pMNV*-SV3CD2
with mutagenic PCR primers MNVSV3CD1_TT29AK_Fwd +
MNVSV3CD1_TT29AK_Rvs and MNVSV3CD1_E54D_Fwd
+ MNVSV3CD1_E54D_Rvs.
The T7-based Escherichia coli expression construct, pSV3C
(pT7-7/SV9), referred to in the present study as pT7-SV3BCD,
has been previously described [35]. Briefly, PCR mutagenesis
was used on template plasmid pSVFrag2 [19] to amplify the SV
NS6 coding region including the surrounding 24 bp of upstream
and 444 bp of downstream SV sequence, and introduce an unique
upstream NdeI and downstream BamHI restriction enzyme site.
The subsequent PCR product was digested with NdeI and BamHI
and introduced into NdeI–BamHI-digested pT7-7 (USB Corp.) to
make pT7-SV3BCD (map and sequence given in Figure S1).
The similar MNV construct, pRSETA-MNV3BCD, was
generated by PCR, using primers NS6_Fwd + NS6_Rvs with
template pMNV*, to amplify the entire NS6 sequence including
the flanking 123 bp of MNV* sequence at both ends. The
amplified PCR product was digested with BamHI and EcoRI and
introduced into the expression vector pRSETA (Invitrogen) at
the BamHI and EcoRI sites. For generating the pRSETA-derived
constructs expressing the domain swap chimaeric proteases, the
unique SalI–Bsu36I fragment from pRSETA-MNV3BCD, which
covers the entire protease gene and upstream/downstream flanking
regions, was exchanged with the equivalent SalI–Bsu36I fragment
from the pMNV* domain swap vectors.
Expression and purification of NS6 protease in E. coli
E. coli overexpression of pRSETA based constructs and
subsequent protease purification was carried out as previously
described [26]. Following the final desalting step the protein
was concentrated to approximately 5 mg/ml and stored in 50%
glycerol.
In vitro kinetic assay for protease activity
Kinetic studies on purified NS6 proteases were performed
as previously described [26], using the synthetic peptide Ac-
DEFQLQ-pNA (Peptide Protein Research) which contains an
acetylated (Ac) N-terminus and a C-terminal p-nitroaniline (pNA)
group to provide a spectrophotometric output. The rate of
cleavage of this substrate (final concentration 0.1–4 mM) by NS6
protease at a final concentration of 0.1 mg/ml was monitored at
415 nm using a iMark plate reader (Bio-Rad) over a 10 min time
period. Results show mean kinetic values of three independent
experiments.
SDS/PAGE and Western blot analysis
SDS/PAGE and Western blot were carried out as previously
described [34]. Primary antibodies to MNV NS proteins used
were rabbit anti-NS4, rabbit anti-NS6, rabbit anti-NS7, and mouse
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anti-NS1/2 [37], mouse anti-NS3 and mouse anti-NS7 [38].
Primary antibody to SV NS6 is a mouse monoclonal antibody
which only detects SV NS6 domain 1 and does not cross react
with MNV NS6. Goat anti-rabbit and goat anti-mouse horseradish
peroxidase conjugates (Sigma–Aldrich) were used as secondary
reagents. Densitometry was conducted using ImageJ imaging
analysis software on duplicate experiments. Data are means with
S.D.
Cell culture and transfection
HEK-293T cells (obtained from the A.T.C.C., LGC Standard)
were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS and GlutaMAX-1 (Invitrogen).
Transfection of HEK-293T cells was performed as previously
described [34] using 1 μg of pMNV* plasmid DNA and 1 μg of
ptTA per well.
Computer modelling of the chimaeric domain swapped protease
structures
Models of the three-dimensional structures of the two domain
swapped chimaeric proteases were produced by least-squares
superposition of the SV and MNV protease structures [26,28].
Following this superposition, the two domains of each protease
were inter-changed and the resulting models were checked for
steric hindrance using the program CONTACT [39,40]. Minor
remodelling where necessary to relieve local poor contacts was
conducted using the graphics program COOT [41]. The theoretical
energetics of the resulting domain interfaces were analysed using
the PISA server [42].
RESULTS
Chimaeric NS6 proteases demonstrate proteolytic activity in E. coli
The structure of MNV and HNV NS6 protease in complex
with boundary substrates and substrate-like inhibitors strongly
suggests that domain 2 is primarily responsible for recognizing
all five NS protein boundaries and dictating cleavage specificity
[26,28,29]. The aim of the present study was to investigate
whether domain 2 of the protease alone dictates boundary
recognition and cleavage by exchanging individual domains from
the MNV protease with the equivalent domain from the HNV
SV protease to construct chimaeric NS6 proteases. Our working
hypothesis was that by exchanging just domain 2 of the protease,
it should be possible to replicate the cleavage specificity observed
by exchanging both domains of the protease.
Alignment of the MNV and SV NS6 20-residue lpeI loop,
which connects the two protease domains, shows that the greatest
sequence identity exists between Met71 and Cys77. It was therefore
decided to splice the domains within the lpeI loop between
residues 72 and 73 (Figure 1). Computer modelling of domain
swap proteases by superposition of the SV and MNV protease
structures [26,28], suggested that the heterologous domains of
MNV and SV NS6 would ‘fit’ together well, indicating that
a chimaeric domain swapped protease was likely to retain
proteolytic activity (Figure 2). Indeed, the two domains of
the chimaeric protease carrying SV domain 1 have a very
favourable predicted interface energy (G = − 21.8 kcal/mol;
1 kcal = 4.184 kJ) and are predicted to form a total of seven
hydrogen bonds and three salt bridges. Likewise, the two domains
of the chimaeric protease carrying SV domain 2, are estimated
to interact with a similar G ( − 22.3 kcal/mol) and form 11
hydrogen bonds and five salt bridges. Both of these values
compare very favourably with the equivalent values of − 19.5
kcal/mol (17 hydrogen bond and 12 salt bridges) for the two
domains of the wild-type SV protease and − 21.1 kcal/mol (six
hydrogen bonds and two salt bridges) for the wild-type MNV
protease, strongly suggesting the chimaeric enzymes are likely to
be as stable as the wild-type proteases.
We first sought to confirm experimentally that heterologously
expressed chimaeric protease would have proteolytic activity
on MNV cleavage boundaries using an E. coli expression
system. This system, developed in our laboratory using wild-
type SV protease, uses a T7 vector to express MNV NS6 flanked
by 41 residues of upstream NS5 sequence and 41 residues
of downstream NS7 sequence to produce a ‘mini’ NS5–NS7
precursor. Fused upstream of the NS5 sequence are 36 amino
acids of vector sequence containing a His tag and Xpress epitope
(Figure 3A). Once expressed in E. coli, the active protease is
able to cleave the upstream NS5NS6 and downstream NS6NS7
boundaries, releasing the 19 kDa mature NS6. This system
was subsequently modified to introduce either SV domain 1,
SV domain 2 or both SV domain 1 and domain 2 in a double
domain swap, in place of the equivalent MNV sequence, and the
production of fully cleaved NS6 was analysed by SDS-PAGE and
Western blot (Figure 3B).
For both MNV and SV wild-type proteases and all three
chimaeric domain swap proteases, a mature NS6 protease band
was clearly observed by SDS-PAGE and confirmed by Western
blot. The full-length SV protease, in both the wild-type context
and with flanking MNV sequence, self-excised completely from
the precursor (Figure 3B, third panel, lanes 4 and 5). However,
the wild-type MNV protease (Figure 3B, second panel, lane 1)
and the two chimaeric domain swap proteases (Figure 3B, second
panel, lanes 2 and 3) showed some residual uncleaved precursors,
as confirmed by Western blot with an NS7 antiserum (Figure
S2). These data confirm that all the chimaeric domain swap
proteases have proteolytic activity on MNV cleavage boundaries,
despite the fact there is some variation in the cleavage of these
boundary substrates, based on the relative amount of residual
precursors remaining. This is most notable when comparing the
wild-type MNV protease with the double domain swap protease
and wild-type SV protease, both of which were fully able to
cleave themselves out of the precursor, demonstrating the wild-
type MNV protease is less active on these boundaries in this assay.
In vitro kinetic analysis of purified chimaeric NS6 proteases
Having established that all the chimaeric NS6 proteases were able
to self-excise from the ‘mini’ NS5–NS7 precursor to yield mature
NS6, we were able to produce highly purified protease from
all five constructs and conduct a comparative kinetic analysis.
The five NS6 proteases were purified from whole E. coli lysates
as previously described and analysed by non-reducing PAGE
(Figure S3) [26]. A major band was observed at approximately
18 kDa for all of the purified enzymes. With the exception of the
chimaeric protease carrying SV domain 2 (MNV/SVD2 NS6),
an additional minor band was observed at approximately 36 kDa
which corresponds to the dimeric form of the NS6 protease as has
previously been observed [13,28,43,44].
Measurements of the initial rate of cleavage were performed for
each chimaeric protease (and wild-type controls) over a 10 min
time period using the chromogenic pNA peptide Ac-DEFQLQ-
pNA, a synthetic substrate representing the SV NS3NS4 cleavage
boundary (Table 1 and Supplementary Figures S4A and S4B).
Little difference was observed in the activity of the wild-type SV
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Figure 1 Schematic representation of the MNV and SV genomes
The genomes of murine norovirus 1 (A) and the human norovirus strain SV (B) are aligned and annotated with the P5–P2′ residues of the ORF1 cleavage sites and a schematic representation of the
NS6 protease with the amino acid sequence found within the lpeI loop. Sequence similarity between the two lpeI loops is indicated in bold. The position where the protease domains were swapped is
indicated on the lpeI sequence.
and MNV proteases in terms of the kcat or Km and thus minimal
variation was observed in activity in terms of their specificity
constant (kcat/Km). Compared with wild-type protease, the double
domain swap chimaera (MNV/SVD1 + D2 NS6) demonstrated
a less than 2-fold reduction in activity in terms of the kcat and a
minor reduction in Km, resulting in overall a less than 2-fold
reduction in activity in terms of specificity constant (kcat/Km). The
chimaeric protease carrying SV domain 1 (MNV/SVD1 NS6) also
showed a reduction in kcat of approximately 3-fold compared with
the wild-type proteases. However, a less than 2-fold reduction
in Km resulted in only a 2-fold overall reduction in activity in
terms of the specificity constant. In contrast, the chimaeric
protease carrying SV domain 2 (MNV/SVD2 NS6) demonstrated
no proteolytic activity on this substrate during the assay period.
Furthermore, increasing the assay period for up to 4 h resulted
in no increase in OD above background levels for this enzyme
(Supplementary Figure S4C).
Chimaeric NS6 proteases have proteolytic activity in MNV
The above data showed that heterologously expressed domain 1
and double domain swap chimaeric proteases have proteolytic
function on both the MNV NS5NS6 and NS6NS7 boundaries,
and on an SV cleavage peptide. Furthermore, although the
chimaeric protease carrying SV domain 2 showed functional
activity in E. coli on the NS5NS6 and NS6NS7 MNV boundaries,
no functional activity was detected on the synthetic substrate
representing the SV NS3NS4 cleavage boundary, suggesting this
enzyme has restricted boundary recognition and therefore limited
proteolysis. However, the in vitro kinetic analysis was limited to
a single synthetic boundary outside the context of a full ORF1
polyprotein and not in the context of a eukaryotic background.
Therefore, to investigate any potential variations in boundary
proteolysis in a full-length ORF1 polyprotein, where all five MNV
cleavage boundaries are present, all three chimaeric proteases
were introduced into MNV*, a construct expressing the entire
MNV cDNA under control of a tTA responsive polII promoter.
Transfection of MNV* constructs into permissive cell lines allows
for export of capped viral transcripts to the cell cytoplasm and
expression of the full ORF1 polyprotein where cleavage of the
NS boundaries can be easily accessed by Western blot. The
chimaeric MNV* constructs and controls were co-transfected into
HEK-293T cells with ptTA, a plasmid expressing the tetracycline
trans-activator allowing for maximal promoter activity, and
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Figure 2 Computer modelling of the domain swap chimaeric norovirus protease
(A) Model showing a superposition of the SV and MNV protease structures in blue and red, respectively, with a HNV substrate-like inhibitor and catalytic triad drawn in ball-and-stick representation.
Both structures suggest that domain 2 of the protease (shown on the left of diagram) is responsible for the majority of the boundary interactions. (B) Computer model of the chimaeric protease in
which domain 1 of the SV NS6 protease (blue) has been fused to domain 2 of the MNV protease (red). (C) The converse chimaera in which domain 2 of the SV NS6 protease (blue) is fused with
domain 1 of the MNV enzyme (red).
NS protein cleavage was assayed by Western blot (Figure 4).
In HNV it is hypothesized that the NS1/2NS3 and NS3NS4
boundaries are the first to be processed, both of which have
glutamine residues at the P1 position [6,16,22]. Therefore, we may
minimally anticipate successful cleavage at the MNV NS3NS4
and NS6NS7 boundaries, both of which have glutamine in the P1
position.
Consistent with this prediction, all chimaeric proteases
demonstrated complete cleavage at the MNV NS3NS4 and
NS6NS7 boundaries which have glutamine residues at the P1
position. Only the chimaeric construct carrying SV domain 1
(MNV/SVD1) showed complete processing at the NS1/2NS3
boundary, yielding mature NS1/2 and NS3. Both chimaeric
constructs carrying either SV domain 1 or SV domain 2
(MNV/SVD1 and MNV/SVD2, respectively) demonstrated little
or no processing at the NS4NS5 and NS5NS6 boundaries,
yielding mainly uncleaved NS4–NS6 and NS5NS6 precursors
and a moderate amount of fully cleaved NS4. Interestingly, the
double domain swap chimaera (MNV/SVD1 + D2) showed
partial processing at both the NS4NS5 and NS5NS6 boundaries,
resulting in a moderate amount of mature NS4 and NS6.
Due to the unavailability of an anti-NS5 antibody capable
of detecting the relatively low abundance of protein in this
system, assignment of NS5 containing precursors was done by
elimination.
Residues within NS6 domain 1 facilitate cleavage at the NS5NS6
boundary
Our original hypothesis was that domain 2 alone interacts with
the boundary sequence to define cleavage specificity. Thus, the
cleavage profile observed by exchanging solely domain 2 should
be the same as exchanging both domains of the protease. Contrary
to this expectation, although the double domain swap chimaera
demonstrated partial cleavage at the NS5NS6 boundary, the
chimaeric protease carrying SV domain 2 showed a complete
block in NS5NS6 processing. This suggests that boundary
specificity is not conferred by domain 2 alone, and domain 1
must contribute some key residues which influence cleavage at
certain NS boundaries.
Potentially a key difference between HNV and MNV proteases
is the change from a glutamic acid to aspartic acid within the
catalytic triad, at position 54 within domain 1 of the enzyme
(Figure 5A). Comparison of the domain 1 residues surrounding the
active site between HNV and MNV showed a further difference
in the residues at positions 28 and 29 (adjacent to His30 of
the catalytic triad), which are changed from two threonines in
SV protease to an alanine and a lysine in the MNV protease
(Figure 5A). To investigate whether these differences in domain 1
could affect boundary recognition and cleavage, PCR mutagenesis
was used to introduce a D54E or AK29TT coding change within
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Figure 3 Analysis of heterologously expressed NS6 domain swap proteases
(A) Schematic representation of the domain swap constructs used for in vitro expression. Unshaded boxes represent wild-type (wt) MNV sequence, whereas light-grey boxes represent wild-type
(wt) SV sequence. The dark grey sequence shows the His tag and Xpress epitope. Curly arrows indicate the positions where the NS6 protease can self excise from the ‘mini’ NS5–NS7 precursor. (B)
SDS-PAGE and Western blot analysis of the expressed chimaeric NS6 proteases. Induced E. coli lysates were analysed by SDS-PAGE and Western blot using antibodies specific for MNV NS6 or
SV NS6. Arrows indicates the position of fully cleaved NS6 proteases which is consistent with their predicted molecular masses. The bands at approximately 27, 23 and 33 kDa correspond to the
predicted molecular masses of the uncleaved ‘mini’ NS5NS6, NS6NS7 and NS5–NS7 precursors, respectively.
Table 1 Kinetic data for the hydrolysis of the substrate DEFQLQ-pNA by
chimaeric NS6 proteases
wt, wild-type.
Enzyme K m (M) k cat (s− 1) k cat/K m (M− 1·s− 1)
wtMNV NS6 2.33×10− 3 0.08 34
MNV/SVD1 NS6 1.53×10− 3 0.03 19.6
MNV/SVD2 NS6 No activity No activity No activity
MNV/SVD1 + D2 NS6 2.16×10− 3 0.06 28
wtSV NS6 2.82×10− 3 0.11 39
the MNV domain 1 sequence of the chimaeric MNV* construct
carrying SV domain 2 (Figure 5B). Such changes represent the
residues which are found at these positions within wild-type SV
protease. In parallel, E54D and TT29AK coding changes were
introduced into the SV domain 1 sequence of the chimaeric MNV*
construct carrying SV domain 1. These changes represent the
residues that are found at these positions within the wild-type
MNV protease (Figure 5B). NS1/2NS3 and NS4–NS6 boundary
cleavage in these new MNV* constructs was analysed by Western
blot using antibodies against NS1/2, MNV NS6 and SV NS6
(Figure 5C).
The chimaeric construct carrying SV domain 1 showed
complete processing at all NS boundaries assayed except the
NS4NS5 and NS5NS6 boundaries, resulting in an accumulation
of uncleaved NS4–NS6 and NS5NS6 precursors. Introducing
the E54D mutation into this construct (MNV/SVD1/E54D) had
no effect on NS boundary cleavage. However, introduction
of the TT29AK mutations (MNV/SVD1/TT29AK) moderately
increased cleavage at the NS5NS6 boundary yielding a limited
amount of mature NS6 protease. The chimaeric construct carrying
the SV domain 2 showed a limitation in cleavage at the NS4NS5
and NS5NS6 boundaries (yielding approximately 37 +− 3%NS4-
6 and 62 +− 3% NS5NS6 by densitometry), in addition to limited
processing of the NS1/2NS3 boundary. Introduction of the
AK29TT mutations within MNV domain 1 of this construct
(MNV/SVD2/AK29TT) resulted in no change in NS boundary
cleavage (approximately 38 +− 0.5% NS4–NS6 and 62 +− 1%
NS5NS6 by densitometry). However, mutation of the aspartic
acid residue at position 54 to a glutamic acid (MNV/SVD2/D54E)
resulted in increased cleavage at the NS5NS6 boundary, yielding
mature NS6 to levels similar to that observed in the double
domain swap chimaeric construct (11 +− 5% compared with
10 +− 7% for MNV/DV2D/D54E and MNV/SVD2, respectively).
Although it is worth noting that this D54E mutant protease
(MNV/SVD2/D54E) still demonstrated a greater proportion of
uncleaved NS4-6 and less NS5NS6 (49%+− 0.2 and 39%+− 6
of NS4-6 and NS5NS6, respectively) when compared with
the double domain swap chimaeric construct (3%+− 0.4 and
87%+− 6 of NS4-6 and NS5NS6, respectively).
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Figure 4 Analysis of NS protein expression in full-length MNV* constructs containing the chimaeric domain swap mutations
(A) Schematic layout of the MNV ORF1 polyprotein with the molecular mass of each NS protein indicated. (B) HEK-293T cells were transfected with full-length wild-type (wt) MNV*, constructs carrying
the chimaeric NS6 proteases (MNV/SVD1, MNV/SVD2 and MNV/SVD1 + D2) or a polymerase knockout construct (MNVGAD), under control of a tetracycline-responsive CMV (cytomegalovirus)
promoter. Maximal promoter activity requires co-transfection with ptTA, a plasmid expressing the tetracycline trans-activator. Control lysate was derived from cells transfected with ptTA only. Cell
lysates were harvested at 24 h post-transfection and probed by Western blot for expression of MNV proteins (NS1/2, NS3, NS4, NS6 and NS7) and SV NS6. The image for NS6 shows a composite
for both anti-MNV NS6 (1) and anti-SV NS6 (2) Western blots. Arrows indicate the positions of full-length proteins and different polyprotein precursors. Note the anti-NS3 antibody detects a
cross-reactive band at approximately 40 kDa which can be clearly seen in the negative control lane.
Glu54 in domain 1 restores minimal kinetic activity of the domain 2
chimaeric enzyme
Introduction of the TT29AK mutation into SV domain 1 of
the chimaeric MNV construct carrying SV domain 1 increased
cleavage at the NS5NS6 boundary, resulting in the release of
some mature NS6. Likewise, introduction of the D54E mutation
into MNV domain 1 of the chimaeric construct carrying SV
domain 2 also resulted in increased cleavage at the NS5NS6
boundary, yielding mature NS6. To examine if such mutations
affected enzyme kinetics, the ‘mini’ NS5–NS7 precursor system
described above was employed to express the chimaeric SV
domain 1 NS6 carrying the TT29AK mutation and the chimaeric
SV domain 2 NS6 carrying the D54E mutation (results not shown).
Purified protease was produced from whole E. coli lysates (results
not shown), and measurements of the initial rate of cleavage
performed, as before, with wild-type MNV and SV proteases
included as internal controls (Table 2).
Little difference was observed in the kinetic activities of
the wild-type MNV or SV NS6 proteases on this substrate
which showed kcat/Km values not significantly different to those
observed in Table 1, demonstrating the reproducibility of this
Table 2 Kinetic data for the hydrolysis of the substrate DEFQLQ-pNA by
chimaeric NS6 proteases containing additional domain 1 mutations
wt, wild-type
Enzyme K m (M) k cat (s− 1) k cat/K m (M− 1·s− 1)
wtMNV NS6 1.0×10− 3 0.053 49
MNV/SVD1/TT29AK NS6 1.65×10− 3 0.0052 3.2
MNV/SVD2/D54E NS6 2.75×10− 3 0.0018 0.7
wtSV NS6 0.7×10− 3 0.053 76
assay. The TT29AK mutation in the chimaeric NS6 carrying SV
domain 1 (MNV/SVD1/TT29AK NS6) resulted in approximately
a 10-fold reduction in kcat when compared with either wild-
type protease, and as a result showed a 10-fold reduction in
the specificity constant (kcat/Km). Conversely, introduction of the
D54E mutation within the chimaeric NS6 carrying SV domain 2
(MNV/SVD2/D54E NS6), restored a minimal level of proteolytic
activity on this substrate, albeit with a 2.5-fold greater Km and
a 30-fold reduction in kcat, resulting in approximately a 70-fold
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Figure 5 Analysis of NS protein expression in chimaeric MNV* constructs carrying additional domain 1 mutations
(A) A superposition of the MNV protease (red) and SV protease (blue) structures indicating the residues which were chosen for mutagenesis. An example cleavage substrate bound to the SV protease
is shown in green. (B) Schematic representation of the chimaeric domain swap proteases carrying additional domain 1 mutations that were introduced into full-length MNV*. Unshaded boxes
indicate MNV sequence, whereas light-grey shaded boxes represent SV sequence. (C) HEK-293T cells were transfected with full-length wild-type (wt) MNV*, constructs carrying the chimaeric NS6
proteases or chimaeric constructs carrying domain 1 additional mutations. Cells were co-transfected with ptTA for maximal promoter activity. Control lysate was derived from cells transfected with
ptTA only. Cell lysates were harvested at 24 h post-transfection and probed by Western blot for expression of MNV NS1/2, MVN NS6 and SV NS6. The image for NS6 shows a composite for both
MNV NS6 (1) and SV NS6 (2) Western blots. Arrows indicate the positions of full-length proteins and different polyprotein precursors.
reduced specificity constant (kcat/Km) when compared with wild-
type protease.
DISCUSSION
Release of the NS proteins from the ORF1 polyprotein in
noroviruses is facilitated by the NS6 protease, which cleaves
at five defined scissile bond dipeptides to yield six mature NS
proteins [6,7,16,17]. The two distinct domains of the norovirus
NS6 protease are separated by the active site groove and linked
by the conserved 20-residue hinge-like lpeI loop [13,26–29]. The
residues which form the active site catalytic triad, and the S5–S1
binding pockets, have been well characterized for both HNV and
MNV protease. For both enzymes, Cys139 has been identified as
the active site nucleophile and His30 as the general base catalyst
which is protonated on the imidazole ring. The acidic third residue
of the triad, Glu54 in HNV and Asp54 in MNV is suggested to
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hydrogen bond with His30 to orientate and stabilize the imidazole
ring. The S1, S2 and S4 binding pockets appear to be the most
critical for substrate binding, the S2 and S4 subsites both forming
particularly deep hydrophobic pockets which overlap and share
residues [13,26–28,31,32].
We sought to investigate whether individual protease domains
conferred specificity to cleavage sites within the MNV ORF1
polyprotein. Our initial hypothesis was that domain 2 of the
protease was the main contributor to substrate specificity,
dictating boundary cleavage. Accordingly, we constructed simple
domain swap chimaeric proteases and re-examined polyprotein
processing. First, it was surprising that proteolytic activity
is retained with all the chimaeric domain swaps, considering
the evolutionary distance between MNV and HNV [45] and the
differences in the structures of the NS6 proteases [26,28]. Both
the chimaeric constructs carrying SV domain 1 or SV domain
2 were able to process the NS3NS4, NS4NS5 and NS6NS7
boundaries to yield mature NS4 and NS7. In addition, chimaeric
NS6 carrying SV domain 1 was able to process the NS1/2NS3
boundary to yield mature NS1/2 and NS3. Upon insertion of
the entire SV protease, in a double domain swap chimaera, the
ORF1 polyprotein was processed at the NS3NS4, NS4NS5 and
NS6NS7 boundaries, additionally, partial cleavage was observed
at the NS5NS6 boundary, yielding moderate amounts of mature
NS5 and NS6. Contrary to our initial hypothesis, our experimental
data showed that the chimaeric protease carrying SV domain 2
demonstrates restricted proteolytic activity compared with the
double domain swap protease, in both in vitro assays and in
the context of a full-length ORF1 polyprotein. These observations
led to our second hypothesis, that domain 1 contributes
critical residues which facilitate cleavage of specific NS protein
boundaries.
Comparison of the domain 1 residues in MNV and HNV that
are predicted to lie close to the boundary substrate and active
site highlighted two strong potential candidate residues that could
influence boundary cleavage. First, the acidic third residue of the
catalytic triad is different between MNV and HNV. Secondly, a
triple neutral-polar stretch of TTT at positions 27–29, just prior
to His30, in HNV is changed to TAK in MNV. Furthermore, both
Glu54 and the triple neutral-polar stretch are conserved across all
HNV sequences (the latter being either TTT or TST depending on
isolate). We therefore hypothesized that some of these differences,
within domain 1 of the protease, could influence cleavage at some
NS protein boundaries. In agreement with these predictions, we
found that introduction of a TT29AK mutation within SV domain
1 of the chimaeric protease carrying MNV domain 2, increased
cleavage at the NS5NS6 boundary, despite showing a 10-fold
reduction in kinetic activity in vitro. Moreover, the D54E mutation
within MNV domain 1 of the chimaeric protease carrying SV
domain 2, restored cleavage at the NS5NS6 boundary to levels
equivalent to the double domain swap chimaera, and restored
minimal activity in vitro on the NS3NS4 substrate.
The X-ray structure of wild-type HNV protease shows that
Glu54 within domain 1 can salt-bridge with Arg112 within
the flexible lpbII loop of domain 2. Furthermore, computer
modelling suggests that this interaction would be weaker
in the chimaeric protease carrying SV domain 2 (which
contains MNV domain 1 and thus Asp54) due to a slightly
shorter side chain. Although it should be noted that the
interaction between Glu54 and Arg112 is somewhat variable in
the available crystal structures, and indeed the structure in which
these residues come the closest together has a partially disrupted
catalytic triad, it is conceivable that the Glu54–Arg112 interaction
is of some physiological importance, not least because this
particular glutamate is the closest negatively charged group to
the guanidinium of Arg112. It would also be anticipated that
re-introduction of Glu54 into MNV domain 1 of the chimaeric
protease carrying SV domain 2, might strengthen this salt bridge
interaction. It is possible that this salt bridge interaction is
important for proteolysis of particular substrates, such as the
NS5NS6 boundary (KINFE-AP). Recently, Muhaxhiri et al. [29]
have observed that the HNV NS6 protease can undergo structural
variation, particularly in the S2 pocket where the protease
adopts a more ‘open’ conformation to accommodate bulkier P2
residues (such as the phenylalanine in KINFE-AP). Taking these
observations into account, and the suggestion that the Glu54–
Arg112 salt bridge interaction is required for HNV NS6-mediated
cleavage of KINFE-AP substrates, it is conceivable that the Glu54–
Arg112 salt bridge interaction is key in stabilizing the more ‘open’
protease structure to allow cleavage of boundaries with larger
P2 residues when glutamic acid is found in the P1 position.
Previous reports have shown that mutation of the acidic Glu54 to a
basic residue (lysine or arginine) is greatly detrimental to protease
stability, and introduction of many hydrophobic residues at this
position restricts cleavage at certain substrate boundaries [32].
However, such restriction was generally observed at boundaries
with small residues at the P2 and P4 positions (such as TATSE-
GK and TTTLE-GK and not KLSFE-AP). In contradiction
to the observations reported here, the same series of studies
demonstrated that mutation of the Glu54 residue to several
alternatives, including aspartic acid, had no effect on processing of
the NS5NS6 boundary, despite showing a 4–5-fold reduction in
kinetic activity on a NS3NS4 boundary substrate [23,32]. This
discrepancy may be explained by the fact that these in vitro
studies were conducted outside the context of the full-length
polyprotein, where secondary factors such as protein folding
intermediates are likely to play a role in substrate proteolysis.
This is further highlighted by the observation that although the
purified NS6 carrying SV domain 2 showed no kinetic activity
in vitro, on a synthetic SV NS3NS4 boundary peptide, it was
able to cleave the MNV NS3NS4 boundary when in the context
of a full ORF1 polyprotein. Comparison of the SV and MNV
NS3NS4 boundaries show little difference in their sequences,
being EFQLQ-GK and DFGLQ-NK, respectively. It is, however,
possible that the difference in the residues at the P3 and P1′
position of these boundaries may account for this difference in
cleavage, given the characterized interactions between domain
2 of HNV and the P3 residue [25]. Taken together these data
illustrate a clear deficiency in using in vitro assays, such as the
use of synthetic boundary peptides with purified proteases, to
draw conclusions about eukaryotic virus biology.
All of the chimaeric constructs were able to efficiently process
the NS3NS4 and NS6NS7 boundaries to completion. This
suggests a preference of both enzymes to cleave substrates with
glutamine in the P1 position, even though structural studies
suggest that the protease makes the same interactions with either
glutamine or glutamic acid in the P1 position [26]. Despite this,
none of the chimaeric proteases, or the double domain swap
protease, were able to fully process the MNV ORF1 polyprotein
to completion. All of the chimaeric constructs were only able
to partially process the NS4NS5 boundary, and in addition all
the constructs carrying SV domain 2, including the double
domain swap construct, were unable to efficiently process the
NS1/2NS3 boundary. The residues at the P2 and P4 position
within these two boundaries for MNV (tryptophan and alanine
for NS1/2NS3 and tyrosine and serine for NS4NS5, respectively)
are not found at these positions within any SV cleavage boundary.
It is therefore feasible that these residues render these boundaries
partially refractory to cleavage by the SV protease. Furthermore,
it would superficially appear that the NS5NS6 boundary is the
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most conserved cleavage boundary between SV and MNV, being
KISFE-AP and KINFE-AP, respectively. However, although wild-
type MNV processed this boundary to completion, only partial
cleavage was observed with the double domain swap chimaera
or the MNV/SVD2/D54E construct. It is possible the difference
in the P3 residue between these two boundaries influences
cleavage efficiency although this is considered unlikely, given
the minimal interaction the P3 residue has with the protease and
that a previously described interaction in HNV protease between
Lys162 and the P3 residue is likely to be conserved in MNV
[25,26]. Alternatively, these differences could reflect a differential
cleavage order and/or cis–trans cleavage requirements of MNV
and HNV or the presence of different functional NS precursors in
HNV. Both stable and/or transient NS protein precursors have
been shown or suggested to have roles in the replication of
several positive strand RNA viruses [46–49]. The NS5-encoded
VPg, which acts as a primer for viral RNA replication, has been
shown to be nucleotidylylated by NS7 in MNV and by NS7 and
NS6NS7 in HNV [50–53]. Even though these studies have shown
that VPg can be nucleotidylylated directly, it is unclear what the
natural substrate for nucleotidylylation is in norovirus infection.
In other positive strand RNA viruses, such, as picornaviruses, the
3BC and 3BCD precursors have been shown to be employed for
uridylylation [54,55], and it is possible a similar precursor is the
natural template for nucleotidylylation in HNV. However, much
of what is understood regarding the order of ORF1 processing
stems from in vitro studies with HNV and in cellulo studies with
MNV, and the exact order of ORF1 processing for either norovirus
and thus the precursors formed, has not yet been defined with a
natural template in cellulo.
To date, none of the crystal structures of norovirus proteases in
complex with boundary substrates or peptide mimics contained
any residues on the P′ side, downstream of the cleavage
junction. Alignment of the amino acid sequences on the P′
side of the boundary reveals no clear amino acid conservation
beyond the preference for smaller residues (glycine or alanine)
in the P1′ position and lysine, glycine, glutamine or proline in
the P2′ position, suggesting the P’ side may have relatively little
influence in dictating boundary cleavage. Indeed, a recent study
with HNV protease showed that substitution of proline for glycine
at the P2′ position resulted in a only a 3-fold decrease in cleavage
efficiency [25]. Despite this, it is difficult to properly assess from
the current crystal studies and biochemical data the interactions
of the norovirus protease with the P′ boundary residues. Crystal
structures of the related picornavirus and sapovirus protease
suggest that some residues on the prime side of the boundaries
have a role in dictating substrate cleavage [56–60]. In the context
of the present study, it is possible that some of the boundary
restrictions observed by swapping domain 1 of the protease were
due to specific recognition between domain 1 of the protease and
the prime side of the junction, as opposed to interactions between
the two domains of the protease.
The lack of a robust cell culture system for HNV has severely
limited the ability to dissect properties of the HNV NS6 protease
in an eukaryotic background and within the context of a complete
ORF1 polyprotein. In the present work, we have established a
new system to study core functions of the NS6 protease. This
system offers significant advantages over the current in vitro
based assays and the few available replicon models in that it
allows for assay of protease cleavage upon multiple boundaries
in the context of a full ORF1 polyprotein, which is temporally
expressed in mammalian cells in a transient system which does
not require the laborious process of establishing stable replicon
cell lines. The technological advancements offered by this new
system, in combination with the current models, offers greater
insights and a deeper understanding of the multi-functional nature
of this apparently simple enzyme which has many complex
interactions.
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